3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Colorectal Neoplasms, Hereditary Nonpolyposis
3
Colorectal Neoplasms
3
Sarcoma
1
Neoplastic Syndromes, Hereditary
1
Neoplasms
1
Microsatellite Instability
1
Hereditary Breast and Ovarian Cancer Syndrome
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
69
Fluorouracil
44
pembrolizumab
43
Oxaliplatin
42
Capecitabine
40
Bevacizumab
37
Leucovorin
36
Irinotecan
31
Cisplatin
27
Nivolumab
24
Paclitaxel
21
Cetuximab
21
Panitumumab
20
130-nm albumin-bound paclitaxel
20
Sorafenib
18
Albumin-Bound Paclitaxel
18
Drug Therapy
15
Docetaxel
15
Cyclophosphamide
15
Radiotherapy
14
Blood Specimen Collection
14
IFL protocol
12
atezolizumab
11
Exercise
11
Taxes
10
budigalimab
9
Erlotinib Hydrochloride
9
trametinib
8
Folfox protocol
8
Carboplatin
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
High-Throughput Nucleotide Sequencing
×
Gastrointestinal
×
Clear all
NCT04261972
2026-01-14
CHARM1
University Health Network, Toronto
Active not recruiting
1,416 enrolled